Volume 20, Number 8—August 2014
Zika Virus Infection after Travel to Tahiti, December 2013
Views: Views equals page views plus PDF downloadsMetric Details
Highlight and copy the desired format.
|EID||Wæhre T, Maagard A, Tappe D, Cadar D, Schmidt-Chanasit J. Zika Virus Infection after Travel to Tahiti, December 2013. Emerg Infect Dis. 2014;20(8):1412-1414. https://dx.doi.org/10.3201/eid2008.140302|
|AMA||Wæhre T, Maagard A, Tappe D, et al. Zika Virus Infection after Travel to Tahiti, December 2013. Emerging Infectious Diseases. 2014;20(8):1412-1414. doi:10.3201/eid2008.140302.|
|APA||Wæhre, T., Maagard, A., Tappe, D., Cadar, D., & Schmidt-Chanasit, J. (2014). Zika Virus Infection after Travel to Tahiti, December 2013. Emerging Infectious Diseases, 20(8), 1412-1414. https://dx.doi.org/10.3201/eid2008.140302.|
To the Editor: Zika virus (ZIKV), a member of the family Flaviviridae, is a mosquito-borne virus that is endemic to Africa and Southeast Asia. ZIKV causes illness that is similar to dengue fever, characterized by joint pain, myalgia, headache, and rash (1). ZIKV has caused several recent outbreaks, including one in Micronesia in 2007 (2) and one in French Polynesia (≈30,000 cases) ongoing since October 2013 (3) and spreading to New Caledonia and Easter Island (4). We report the clinical and laboratory findings for a patient with ZIKV infection imported from Tahiti, French Polynesia.
The previously healthy 31-year-old woman from Norway was admitted to the Oslo University Hospital, Norway, on December 13, 2013. Six days earlier, she had returned from a 14-day vacation to Tahiti, where she mainly stayed in the capital, Pape'ete, and took a short trip to the island of Mo'orea. One day after her return to Norway, she experienced fever, intense joint pain, and myalgia. Subsequently, a maculopapular rash developed. At the time of admission, her temperature was 37.7°C, and she had enlarged nuchal lymph nodes; injected conjunctivae; and a maculopapular rash on her trunk, extremities, and face (Technical Appendix). Clinical examination findings were otherwise unremarkable. Laboratory tests showed leukopenia of 2.7 × 109 cells/L (reference range 3.5–10 × 109/L), with mild lymphopenia of 1.0 × 109 cells/L (reference range 1.5.–4.0 × 109/L) and neutropenia of 1.4 ×109 cells/L (reference range 1.5–7.3 × 109/L). No thrombocytopenia or elevated liver enzyme levels were detected. C-reactive protein levels (1.4 mg/L) were within reference range.
Because of the patient’s clinical picture and travel history, an acute ZIKV infection was suspected and several diagnostic tests were ordered. In a serum sample taken 5 days after symptom onset, no IgM or IgG against ZIKV, dengue virus (DENV), Japanese encephalitis virus, yellow fever virus, or chikungunya virus was detected by in-house indirect immunofluorescence (5,6). Only a weak IgG titer of 1:20 (and no IgM) against tick-borne encephalitis virus was found (cutoff <1:20). Test results for DENV nonstructural protein 1 antigen (Platelia; Bio-Rad, Hercules, CA, USA) and generic flavivirus reverse transcription PCR (RT-PCR) (6) were negative. Thus, for increased sensitivity, quantitative ZIKV-specific real-time RT-PCR (6) with the AgPath-ID One-Step RT-PCR Kit (Life Technologies, Carlsbad, CA, USA) was performed according to the manufacturer’s instructions, and results were positive. ZIKV RNA load was 1.6 × 105 copies/mL; in vitro–transcribed RNA from a reference plasmid was used as a quantification standard.
Attempts to isolate ZIKV in cell culture failed. Therefore, the serum sample was used to obtain the partial ZIKV genome sequence with primers designed from multiple alignments of partial ZIKV genomes retrieved from databases. Primer sequences used for partial genome amplification of ZIKV are available on request (to J. S.-C.). The partial ZIKV genome (strain Tahiti, GenBank accession no. KJ461621) was successfully amplified from the serum sample, and phylogenetic analysis of an ≈200-bp long genomic fragment of the nonstructural protein 3 gene demonstrated that strain Tahiti clusters within the Asian ZIKV lineages and is closely related to a strain from Malaysia (Figure).
In a follow-up serum sample collected 36 days after symptom onset, IgG and IgM seroconversion against ZIKV was demonstrated; IgM titer was 1:1,280 and IgG titer was 1:2,560 (cutoff <1:20). In the same sample, low IgG titers against tick-borne encephalitis virus and DENV (1:40 and 1:80, respectively) were noted (cutoffs <1:20). Real-time RT-PCR for ZIKV in this serum sample was negative.
Travel-related imported ZIKV infections have been reported after travel from Thailand to Germany (6) and Canada (7), from Indonesia to Australia (8), and from Senegal to the United States (9). Linked to the current outbreak in French Polynesia, infections in 2 travelers who had returned from Bora Bora to Japan have recently been described (10). The clinical findings for the patient reported here (fever, rash, arthralgia, myalgia) were similar to those previously reported for patients with imported cases (6,10). Available laboratory data are meager, but mild thrombocytopenia has been reported for some patients with Zika fever (10), but not for others (6,8). Outbreaks of dengue fever also occur in French Polynesia (10), making dengue fever clinically and epidemiologically the most important differential diagnosis. Elevated liver enzymes, which are found in patients with acute dengue fever, are found in some, but not all, patients with Zika fever (6,8).
The measured viral load for the patient reported here (5 days after symptom onset) would not be high enough for efficient transmission of ZIKV to susceptible vectors such as Aedes aegypti or Ae. albopictus mosquitoes (S. Becker, pers. comm.). This finding is consistent with previously reported findings of ZIKV RNA loads of 930–728,800 copies/mL (2). However, Ae. aegypti and Ae. albopictus mosquitoes are not present in Norway; thus, transmission in Norway seems unlikely. ZIKV infection should be considered as a differential diagnosis for febrile dengue fever–like syndromes in travelers who have returned from Southeast Asia and the Pacific region.
We thank Claudia Poggensee, Mathis Petersen, Alexandra Bialonski, Insa Bonow, Corinna Thomé, and Birgit Hüsing for technical assistance.
This letter is dedicated to the late Ursula Herrmann (1927–2014), who made this study possible.
- Hayes EB. Zika virus outside Africa. Emerg Infect Dis. 2009;15:1347–50 .
- Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232–9.
- European Centre for Disease Prevention and Control. Zika virus–Pacific (08). ProMed. 2014 Mar 16. http://www.promedmail.org, archive no. 20140316.2335754.
- Tappe D, Schmidt-Chanasit J, Ries A, Ziegler U, Müller A, Stich A. Ross River virus infection in a traveller returning from northern Australia. Med Microbiol Immunol (Berl). 2009;198:271–3.
- Tappe D, Rissland J, Gabriel M, Emmerich P, Gunther S, Held G, First case of laboratory-confirmed Zika virus infection imported to Europe, November 2013. Euro Surveill. 2014;19:20685 .
- Fonseca K. Zika virus–Canada ex Thailand. ProMed. 2013 May 29. http://www.promedmail.org, archive no. 20130529.1744108.
- Kwong JC, Druce JD, Leder K. Zika virus infection acquired during brief travel to Indonesia. Am J Trop Med Hyg. 2013;89:516–7.
- Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD, Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis. 2011;17:880–2.
- Kutsuna S, Kato Y, Takasaki T, Moi ML, Kotaki A, Uemura H. Two cases of Zika virus imported from French Polynesia to Japan, December 2013 to January 2014. Euro Surveill. 2014;19:pi=20683.
FigureCite This Article
1These authors contributed equally to this article.
- Page created: July 21, 2014
- Page last updated: July 21, 2014
- Page last reviewed: July 21, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)